Stellar Biotechnologies Inc (SBOT) Stock Faces Higher Risks Forward After Forming Bearish Double Bottom Pattern

September 17, 2017 - By Marry Poplack

The chart of Stellar Biotechnologies Inc (SBOT) shows a double bottom with $1.06 target or 9.00 % below today’s $1.16 share price. The 5 months chart pattern indicates high risk for the $12.22M company. It was reported on Sep, 17 by Finviz.com. If the $1.06 price target is reached, the company will be worth $1.10M less. Double bottoms are rare but powerful chart patterns.

The stock 0.14% or $0 on September 15, reaching $1.16. It is down 60.19% since September 17, 2016 and is downtrending. It has underperformed by 76.89% the S&P500.

Analysts expect Stellar Biotechnologies Inc (NASDAQ:SBOT) to report $-0.14 EPS on December, 13.They anticipate $0.01 EPS change or 7.69 % from last quarter’s $-0.13 EPS. After having $-0.12 EPS previously, Stellar Biotechnologies Inc’s analysts see 16.67 % EPS growth.

More notable recent Stellar Biotechnologies Inc (NASDAQ:SBOT) news were published by: Marketwatch.com which released: “1.16” on November 05, 2015, also Marketwired.com with their article: “Stellar Biotechnologies and Neovacs Announce Formation of New Company Neostell …” published on July 19, 2016, Globenewswire.com published: “Neovacs Associates Stellar Biotechnologies in Its Industrial Project” on January 21, 2016. More interesting news about Stellar Biotechnologies Inc (NASDAQ:SBOT) were released by: Marketwired.com and their article: “Stellar Biotechnologies Advances Strategic Plan to Secure Key Production Region” published on January 11, 2017 as well as Barrons.com‘s news article titled: “Stellar Biotechnologies Gets a Positive Sign” with publication date: February 25, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: